You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluvoxamine
Accession NumberDB00176  (APRD00425)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.

Structure
Thumb
Synonyms
Fluvoxamina
Fluvoxamine
Fluvoxaminum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Fluvoxaminetablet50 mgoralActavis Pharma Company2004-08-13Not applicableCanada
Act Fluvoxaminetablet100 mgoralActavis Pharma Company2004-08-13Not applicableCanada
Ava-fluvoxaminetablet100 mgoralAvanstra Inc2011-08-222014-08-21Canada
Ava-fluvoxaminetablet50 mgoralAvanstra Inc2011-08-222014-08-21Canada
Bci Fluvoxamine Tabletstablet100.0 mgoralBaker Cummins Inc2005-07-042006-10-03Canada
Bci Fluvoxamine Tabletstablet50.0 mgoralBaker Cummins Inc2005-07-042006-10-03Canada
Dom-fluvoxaminetablet100 mgoralDominion Pharmacal2000-02-23Not applicableCanada
Dom-fluvoxaminetablet50 mgoralDominion Pharmacal2000-02-23Not applicableCanada
Fluvoxamine Maleatetablet25 mg/1oralStat Rx USA2008-04-14Not applicableUs
Fluvoxamine Maleatetablet, coated100 mg/1oralANI Pharmaceuticals, Inc.2011-08-09Not applicableUs
Fluvoxamine Maleatetablet, coated50 mg/1oralANI Pharmaceuticals, Inc.2011-08-09Not applicableUs
Fluvoxamine Maleatetablet, coated25 mg/1oralANI Pharmaceuticals, Inc.2011-08-09Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralREMEDYREPACK INC.2012-10-15Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralREMEDYREPACK INC.2013-09-11Not applicableUs
Fluvoxamine Maleatetablet, coated50 mg/1oralAidarex Pharmaceuticals LLC2011-08-09Not applicableUs
Fluvoxamine Tabletstablet100 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Fluvoxamine Tabletstablet50 mgoralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Fluvoxamine-100tablet100 mgoralPro Doc Limitee1998-04-10Not applicableCanada
Fluvoxamine-50tablet50 mgoralPro Doc Limitee1998-04-10Not applicableCanada
Gen-fluvoxamine 100mgtablet100 mgoralGenpharm Ulc1999-09-152002-01-11Canada
Gen-fluvoxamine 50mgtablet50 mgoralGenpharm Ulc1999-09-152002-01-11Canada
Luvoxtablet50 mgoralBgp Pharma Ulc1991-12-31Not applicableCanada
Luvoxtablet100 mgoralBgp Pharma Ulc1991-12-31Not applicableCanada
Luvox CRcapsule, extended release150 mg/1oralJazz Pharmaceuticals, Inc.2008-02-28Not applicableUs
Luvox CRcapsule, extended release100 mg/1oralJazz Pharmaceuticals, Inc.2008-02-28Not applicableUs
Novo-fluvoxaminetablet50 mgoralTeva Canada Limited1999-04-30Not applicableCanada
Novo-fluvoxaminetablet100 mgoralTeva Canada Limited1999-04-30Not applicableCanada
Nu-fluvoxamine 100 Mg Tabtablet100 mgoralNu Pharm Inc1998-10-302012-09-04Canada
Nu-fluvoxamine 50 Mg Tabtablet50 mgoralNu Pharm Inc1998-10-302012-09-04Canada
PHL-fluvoxaminetablet100 mgoralPharmel Inc2005-03-23Not applicableCanada
PHL-fluvoxaminetablet50 mgoralPharmel Inc2005-03-23Not applicableCanada
PMS-fluvoxaminetablet50 mgoralPharmascience Inc1999-09-02Not applicableCanada
PMS-fluvoxaminetablet100 mgoralPharmascience Inc1999-10-12Not applicableCanada
Ratio-fluvoxaminetablet100 mgoralTeva Canada Limited1997-06-12Not applicableCanada
Ratio-fluvoxaminetablet50 mgoralTeva Canada Limited1997-06-12Not applicableCanada
Riva-fluvoxtablet100 mgoralLaboratoire Riva Inc2008-06-11Not applicableCanada
Riva-fluvoxtablet50 mgoralLaboratoire Riva Inc2008-06-11Not applicableCanada
Riva-fluvox 100mg Tabletstablet100 mgoralLaboratoire Riva Inc1999-08-272003-07-28Canada
Riva-fluvox 50mg Tabletstablet50 mgoralLaboratoire Riva Inc1999-08-272003-07-28Canada
Sandoz Fluvoxaminetablet100 mgoralSandoz Canada Incorporated2003-02-27Not applicableCanada
Sandoz Fluvoxaminetablet50 mgoralSandoz Canada Incorporated2003-02-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluvoxamine Tabletstablet50 mgoralApotex Inc1997-05-20Not applicableCanada
Apo-fluvoxamine Tabletstablet100 mgoralApotex Inc1998-05-20Not applicableCanada
Fluvoxamine Maleatetablet50 mg/1oralREMEDYREPACK INC.2011-11-30Not applicableUs
Fluvoxamine Maleatetablet, film coated25 mg/1oralEon Labs, Inc.2000-11-29Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralMylan Institutional Inc.2002-09-15Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2000-12-20Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralGolden State Medical Supply, Inc.2001-05-07Not applicableUs
Fluvoxamine Maleatecapsule, extended release150 mg/1oralTorrent Pharmaceuticals Limited2014-10-31Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralAmerican Health Packaging2014-09-29Not applicableUs
Fluvoxamine Maleatetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.2000-12-20Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralGolden State Medical Supply, Inc.2001-05-07Not applicableUs
Fluvoxamine Maleatecapsule, extended release100 mg/1oralTorrent Pharmaceuticals Limited2014-10-31Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralbryant ranch prepack2000-11-29Not applicableUs
Fluvoxamine Maleatecapsule, extended release150 mg/1oralActavis Pharma, Inc.2014-08-05Not applicableUs
Fluvoxamine Maleatetablet25 mg/1oralGolden State Medical Supply, Inc.2001-05-07Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralbryant ranch prepack2010-03-12Not applicableUs
Fluvoxamine Maleatecapsule, extended release100 mg/1oralActavis Pharma, Inc.2014-08-05Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2006-02-23Not applicableUs
Fluvoxamine Maleatetablet100 mg/1oralApotex Corp2001-07-10Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralEon Labs, Inc.2000-11-29Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2006-02-23Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-03-12Not applicableUs
Fluvoxamine Maleatetablet50 mg/1oralApotex Corp2001-07-10Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralMylan Institutional Inc.2002-09-15Not applicableUs
Fluvoxamine Maleatetablet, film coated50 mg/1oralEon Labs, Inc.2000-11-29Not applicableUs
Fluvoxamine Maleatetablet25 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2006-02-23Not applicableUs
Fluvoxamine Maleatetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2000-12-20Not applicableUs
Fluvoxamine Maleatetablet25 mg/1oralApotex Corp2001-07-10Not applicableUs
Fluvoxamine Maleate Extended-releasecapsule, extended release150 mg/1oralPar Pharmaceutical, Inc.2013-03-13Not applicableUs
Fluvoxamine Maleate Extended-releasecapsule, extended release100 mg/1oralPar Pharmaceutical, Inc.2013-03-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DumiroxAbbott
FaverinAbbott
FevarinAbbott
FloxyfralAbbott
MaveralAbbott
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fluvoxamine maleate
ThumbNot applicableDBSALT000879
Categories
UNIIO4L1XPO44W
CAS number54739-18-3
WeightAverage: 318.3346
Monoisotopic: 318.155512541
Chemical FormulaC15H21F3N2O2
InChI KeyInChIKey=CJOFXWAVKWHTFT-XSFVSMFZSA-N
InChI
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
IUPAC Name
(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine
SMILES
COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Oxime ether
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Primary aliphatic amine
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.
PharmacodynamicsFluvoxamine, an aralkylketone-derivative agent, is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) that differs structurally from other SSRIs. It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Fluvoxamine does not inhibit monoamine oxidase.
Mechanism of actionThe exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, histamine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors.
Related Articles
AbsorptionWell absorbed, bioavailability of fluvoxamine maleate is 53%.
Volume of distribution
  • 25 L/kg
Protein binding~77-80% (plasma protein)
Metabolism

Hepatic

SubstrateEnzymesProduct
Fluvoxamine
fluvoxamino acidDetails
Route of eliminationThe main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. Approximately 2% of fluvoxamine was excreted in urine unchanged. Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.
Half life15.6 hours
ClearanceNot Available
ToxicitySide effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9775
Caco-2 permeable-0.5149
P-glycoprotein substrateSubstrate0.6079
P-glycoprotein inhibitor IInhibitor0.7883
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.5325
CYP450 2C9 substrateNon-substrate0.8595
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6723
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8481
Ames testNon AMES toxic0.5
CarcinogenicityNon-carcinogens0.637
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6997 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8427
hERG inhibition (predictor II)Inhibitor0.7995
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Jazz pharmaceuticals
  • Actavis elizabeth llc
  • Apotex inc
  • Barr laboratories inc
  • Caraco pharmaceutical laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Synthon pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Ani pharmaceuticals inc
  • Solvay pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Tabletoral100.0 mg
Tabletoral50.0 mg
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral150 mg/1
Tabletoral100 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tablet, coatedoral100 mg/1
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tabletoral100 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Luvox CR 150 mg 24 Hour Capsule6.34USD capsule
Luvox cr 150 mg capsule6.24USD capsule
Luvox CR 100 mg 24 Hour Capsule6.05USD capsule
Luvox cr 100 mg capsule5.82USD capsule
Fluvoxamine maleate 100 mg tablet2.69USD tablet
Fluvoxamine mal 100 mg tablet2.63USD tablet
Fluvoxamine maleate 50 mg tablet2.61USD tablet
Fluvoxamine maleate 25 mg tablet2.34USD tablet
Luvox 100 mg Tablet1.7USD tablet
Luvox 50 mg Tablet0.95USD tablet
Apo-Fluvoxamine 100 mg Tablet0.93USD tablet
Co Fluvoxamine 100 mg Tablet0.93USD tablet
Novo-Fluvoxamine 100 mg Tablet0.93USD tablet
Nu-Fluvoxamine 100 mg Tablet0.93USD tablet
Pms-Fluvoxamine 100 mg Tablet0.93USD tablet
Ratio-Fluvoxamine 100 mg Tablet0.93USD tablet
Sandoz Fluvoxamine 100 mg Tablet0.93USD tablet
Apo-Fluvoxamine 50 mg Tablet0.52USD tablet
Co Fluvoxamine 50 mg Tablet0.52USD tablet
Novo-Fluvoxamine 50 mg Tablet0.52USD tablet
Nu-Fluvoxamine 50 mg Tablet0.52USD tablet
Pms-Fluvoxamine 50 mg Tablet0.52USD tablet
Ratio-Fluvoxamine 50 mg Tablet0.52USD tablet
Sandoz Fluvoxamine 50 mg Tablet0.52USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7465462 No2000-05-102020-05-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120-121.5 °CWelle, H.B.A. and Claassen, V.; U.S. Patent 4,085,225; April 18, 1978; assigned to U.S. Phillips Corp.
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00734 mg/mLALOGPS
logP2.89ALOGPS
logP2.8ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area56.84 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity79.2 m3·mol-1ChemAxon
Polarizability32.44 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Welle, H.B.A. and Claassen, V.; U.S. Patent 4,085,225; April 18, 1978; assigned to U.S. Phillips Corp.

General References
  1. Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. [PubMed:16316311 ]
  2. Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. [PubMed:18568110 ]
External Links
ATC CodesN06AB08
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (633 KB)
MSDSDownload (48.5 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Fluvoxamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluvoxamine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Fluvoxamine.
AbirateroneThe serum concentration of Fluvoxamine can be increased when it is combined with Abiraterone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Fluvoxamine.
AcarboseFluvoxamine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fluvoxamine.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Fluvoxamine.
AcenocoumarolFluvoxamine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluvoxamine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluvoxamine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Fluvoxamine.
AcetophenazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Fluvoxamine.
Acetylsalicylic acidFluvoxamine may increase the antiplatelet activities of Acetylsalicylic acid.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Fluvoxamine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Fluvoxamine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluvoxamine.
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Fluvoxamine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluvoxamine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Fluvoxamine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Fluvoxamine.
AlbiglutideFluvoxamine may increase the hypoglycemic activities of Albiglutide.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Fluvoxamine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fluvoxamine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluvoxamine.
AlfentanilAlfentanil may increase the serotonergic activities of Fluvoxamine.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Fluvoxamine.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Fluvoxamine.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fluvoxamine.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Fluvoxamine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fluvoxamine.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Fluvoxamine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Fluvoxamine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluvoxamine.
AlogliptinFluvoxamine may increase the hypoglycemic activities of Alogliptin.
AlosetronThe metabolism of Alosetron can be decreased when combined with Fluvoxamine.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Fluvoxamine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Alphacetylmethadol.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Fluvoxamine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluvoxamine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Fluvoxamine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Fluvoxamine.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Fluvoxamine.
AmineptineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Fluvoxamine.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Fluvoxamine.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Fluvoxamine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluvoxamine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluvoxamine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Fluvoxamine.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Fluvoxamine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluvoxamine.
AmoxapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amoxapine.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Fluvoxamine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fluvoxamine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Fluvoxamine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Fluvoxamine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Fluvoxamine.
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Fluvoxamine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Fluvoxamine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fluvoxamine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Fluvoxamine.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Fluvoxamine.
AprindineThe metabolism of Aprindine can be decreased when combined with Fluvoxamine.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Fluvoxamine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Fluvoxamine.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Fluvoxamine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluvoxamine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluvoxamine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Fluvoxamine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fluvoxamine.
ASA404The metabolism of ASA404 can be decreased when combined with Fluvoxamine.
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Fluvoxamine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluvoxamine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Fluvoxamine.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Fluvoxamine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fluvoxamine.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Fluvoxamine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Fluvoxamine.
AV650The metabolism of AV650 can be decreased when combined with Fluvoxamine.
AvanafilThe metabolism of Avanafil can be decreased when combined with Fluvoxamine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Fluvoxamine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluvoxamine.
AzelastineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluvoxamine.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Fluvoxamine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluvoxamine.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Fluvoxamine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluvoxamine.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Fluvoxamine.
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Fluvoxamine.
BendroflumethiazideFluvoxamine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Fluvoxamine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Fluvoxamine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluvoxamine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Fluvoxamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluvoxamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Fluvoxamine.
BepridilThe metabolism of Bepridil can be decreased when combined with Fluvoxamine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fluvoxamine.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Fluvoxamine.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Fluvoxamine.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Fluvoxamine.
BezitramideBezitramide may increase the serotonergic activities of Fluvoxamine.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Fluvoxamine.
BifeprunoxThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bifeprunox.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Fluvoxamine.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Fluvoxamine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Fluvoxamine.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Fluvoxamine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluvoxamine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluvoxamine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fluvoxamine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fluvoxamine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
BrimonidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Brimonidine.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Fluvoxamine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluvoxamine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Fluvoxamine.
BromocriptineFluvoxamine may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluvoxamine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fluvoxamine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Fluvoxamine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fluvoxamine.
BudesonideThe metabolism of Budesonide can be decreased when combined with Fluvoxamine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Fluvoxamine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluvoxamine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Fluvoxamine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Fluvoxamine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Fluvoxamine.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluvoxamine.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Fluvoxamine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluvoxamine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Fluvoxamine.
BusulfanThe metabolism of Busulfan can be decreased when combined with Fluvoxamine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluvoxamine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fluvoxamine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluvoxamine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fluvoxamine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluvoxamine.
ButorphanolButorphanol may increase the serotonergic activities of Fluvoxamine.
ButorphanolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butorphanol.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Fluvoxamine.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Fluvoxamine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluvoxamine.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Fluvoxamine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Fluvoxamine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Fluvoxamine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fluvoxamine.
CanagliflozinFluvoxamine may increase the hypoglycemic activities of Canagliflozin.
CandesartanThe metabolism of Candesartan can be decreased when combined with Fluvoxamine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Fluvoxamine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluvoxamine.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fluvoxamine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fluvoxamine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluvoxamine.
CarfentanilCarfentanil may increase the serotonergic activities of Fluvoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fluvoxamine.
CariprazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluvoxamine.
CarmustineThe metabolism of Carmustine can be decreased when combined with Fluvoxamine.
CaroxazoneCaroxazone may increase the serotonergic activities of Fluvoxamine.
CarteololThe metabolism of Carteolol can be decreased when combined with Fluvoxamine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Fluvoxamine.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Fluvoxamine.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Fluvoxamine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Fluvoxamine.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Fluvoxamine.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Fluvoxamine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluvoxamine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Fluvoxamine.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Fluvoxamine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluvoxamine.
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Fluvoxamine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluvoxamine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Fluvoxamine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluvoxamine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluvoxamine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Fluvoxamine.
ChlorothiazideFluvoxamine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluvoxamine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Fluvoxamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluvoxamine.
ChlorpropamideFluvoxamine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluvoxamine.
ChlorthalidoneFluvoxamine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluvoxamine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Fluvoxamine.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Fluvoxamine.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Fluvoxamine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Fluvoxamine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Fluvoxamine.
CimetidineThe metabolism of Fluvoxamine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Fluvoxamine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluvoxamine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Fluvoxamine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fluvoxamine.
CisaprideThe metabolism of Cisapride can be decreased when combined with Fluvoxamine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fluvoxamine.
CitalopramThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Citalopram.
CitalopramThe metabolism of Fluvoxamine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Fluvoxamine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fluvoxamine.
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Fluvoxamine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Fluvoxamine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluvoxamine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Fluvoxamine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fluvoxamine.
ClobazamThe metabolism of Clobazam can be decreased when combined with Fluvoxamine.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Fluvoxamine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Fluvoxamine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fluvoxamine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Fluvoxamine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fluvoxamine.
ClomipramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fluvoxamine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Fluvoxamine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluvoxamine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Fluvoxamine.
ClopidogrelThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluvoxamine.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Fluvoxamine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Fluvoxamine.
ClotrimazoleThe metabolism of Fluvoxamine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluvoxamine.
CobicistatThe serum concentration of Fluvoxamine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fluvoxamine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluvoxamine.
CocaineThe metabolism of Cocaine can be decreased when combined with Fluvoxamine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluvoxamine.
CodeineCodeine may increase the serotonergic activities of Fluvoxamine.
ColchicineThe metabolism of Colchicine can be decreased when combined with Fluvoxamine.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Fluvoxamine.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Fluvoxamine.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Fluvoxamine.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Fluvoxamine.
CyamemazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fluvoxamine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluvoxamine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Fluvoxamine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Fluvoxamine.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.
CyproheptadineThe therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Fluvoxamine can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Fluvoxamine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluvoxamine.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Fluvoxamine.
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Fluvoxamine.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Fluvoxamine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fluvoxamine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluvoxamine.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Fluvoxamine.
DapagliflozinFluvoxamine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluvoxamine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluvoxamine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluvoxamine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Fluvoxamine.
DarunavirThe serum concentration of Fluvoxamine can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Fluvoxamine.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Fluvoxamine.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Fluvoxamine.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Fluvoxamine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fluvoxamine.
DeferasiroxThe serum concentration of Fluvoxamine can be increased when it is combined with Deferasirox.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Fluvoxamine.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Fluvoxamine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Fluvoxamine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluvoxamine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluvoxamine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Fluvoxamine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluvoxamine.
DesmopressinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Fluvoxamine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluvoxamine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fluvoxamine.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Fluvoxamine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluvoxamine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Fluvoxamine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluvoxamine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Fluvoxamine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Fluvoxamine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Fluvoxamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluvoxamine.
DextromoramideDextromoramide may increase the serotonergic activities of Fluvoxamine.
DextromoramideThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Fluvoxamine.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Fluvoxamine.
DezocineDezocine may increase the serotonergic activities of Fluvoxamine.
DezocineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluvoxamine.
DiazepamThe metabolism of Diazepam can be decreased when combined with Fluvoxamine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Fluvoxamine.
DicoumarolFluvoxamine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluvoxamine.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fluvoxamine.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Fluvoxamine.
DigoxinThe metabolism of Digoxin can be decreased when combined with Fluvoxamine.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Fluvoxamine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Fluvoxamine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Fluvoxamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluvoxamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Fluvoxamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Fluvoxamine.
DihydromorphineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fluvoxamine.
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Fluvoxamine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluvoxamine.
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Fluvoxamine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluvoxamine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Fluvoxamine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Fluvoxamine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluvoxamine.
DisopyramideFluvoxamine may increase the hypoglycemic activities of Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Fluvoxamine.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Fluvoxamine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Fluvoxamine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Fluvoxamine.
DolasetronDolasetron may increase the serotonergic activities of Fluvoxamine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fluvoxamine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Fluvoxamine.
DopamineThe metabolism of Dopamine can be decreased when combined with Fluvoxamine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fluvoxamine.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Fluvoxamine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fluvoxamine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Fluvoxamine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluvoxamine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Fluvoxamine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Fluvoxamine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
DoxylamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Doxylamine.
DPDPEDPDPE may increase the serotonergic activities of Fluvoxamine.
DPDPEThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Fluvoxamine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Fluvoxamine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fluvoxamine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluvoxamine.
DulaglutideFluvoxamine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluvoxamine.
DuloxetineThe metabolism of Fluvoxamine can be decreased when combined with Duloxetine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Fluvoxamine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluvoxamine.
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Fluvoxamine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluvoxamine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fluvoxamine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluvoxamine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fluvoxamine.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Fluvoxamine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Fluvoxamine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluvoxamine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Fluvoxamine.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Fluvoxamine.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Fluvoxamine.
EmpagliflozinFluvoxamine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Fluvoxamine.
EncainideThe metabolism of Encainide can be decreased when combined with Fluvoxamine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Fluvoxamine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluvoxamine.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Fluvoxamine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluvoxamine.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Fluvoxamine.
EpinastineThe metabolism of Epinastine can be decreased when combined with Fluvoxamine.
EplerenoneThe metabolism of Eplerenone can be decreased when combined with Fluvoxamine.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Fluvoxamine.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Fluvoxamine.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Fluvoxamine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluvoxamine.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Fluvoxamine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluvoxamine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Fluvoxamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluvoxamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Fluvoxamine.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Fluvoxamine.
EscitalopramThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Escitalopram.
EscitalopramEscitalopram may increase the serotonergic activities of Fluvoxamine.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Fluvoxamine.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Fluvoxamine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluvoxamine.
EstazolamThe metabolism of Estazolam can be decreased when combined with Fluvoxamine.
EstradiolThe metabolism of Estradiol can be decreased when combined with Fluvoxamine.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Fluvoxamine.
EstramustineThe metabolism of Estramustine can be decreased when combined with Fluvoxamine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Fluvoxamine.
EstroneThe metabolism of Estrone can be decreased when combined with Fluvoxamine.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Fluvoxamine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluvoxamine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Fluvoxamine.
EthanolFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluvoxamine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluvoxamine.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Fluvoxamine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluvoxamine.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Fluvoxamine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluvoxamine.
Ethyl biscoumacetateFluvoxamine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluvoxamine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluvoxamine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Fluvoxamine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Fluvoxamine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fluvoxamine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fluvoxamine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fluvoxamine.
EtodolacThe metabolism of Etodolac can be decreased when combined with Fluvoxamine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluvoxamine.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Fluvoxamine.
EtoperidoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etoperidone.
EtoperidoneEtoperidone may increase the serotonergic activities of Fluvoxamine.
EtoposideThe metabolism of Etoposide can be decreased when combined with Fluvoxamine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Fluvoxamine.
EtorphineEtorphine may increase the serotonergic activities of Fluvoxamine.
EtorphineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etorphine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Fluvoxamine.
EverolimusThe metabolism of Everolimus can be decreased when combined with Fluvoxamine.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Fluvoxamine.
ExenatideFluvoxamine may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fluvoxamine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Fluvoxamine.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Fluvoxamine.
FamotidineThe metabolism of Famotidine can be decreased when combined with Fluvoxamine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Fluvoxamine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Fluvoxamine.
FelodipineThe metabolism of Felodipine can be decreased when combined with Fluvoxamine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluvoxamine.
FenfluramineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fenfluramine.
FenfluramineFenfluramine may increase the serotonergic activities of Fluvoxamine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Fluvoxamine.
FentanylFentanyl may increase the serotonergic activities of Fluvoxamine.
FentanylThe metabolism of Fentanyl can be decreased when combined with Fluvoxamine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvoxamine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fluvoxamine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fluvoxamine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fluvoxamine.
FinasterideThe metabolism of Finasteride can be decreased when combined with Fluvoxamine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Fluvoxamine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Fluvoxamine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Fluvoxamine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluvoxamine.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluvoxamine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluvoxamine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Fluvoxamine.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Fluvoxamine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluvoxamine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Fluvoxamine.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Fluvoxamine.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Fluvoxamine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluoxetine.
FluoxetineFluoxetine may increase the serotonergic activities of Fluvoxamine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluvoxamine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluvoxamine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluvoxamine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Fluvoxamine.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Fluvoxamine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluvoxamine.
FlutamideThe metabolism of Flutamide can be decreased when combined with Fluvoxamine.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Fluvoxamine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fluvoxamine.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Fluvoxamine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Fluvoxamine.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Fluvoxamine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluvoxamine.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Fluvoxamine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluvoxamine.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Fluvoxamine.
FurazolidoneFurazolidone may increase the serotonergic activities of Fluvoxamine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluvoxamine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Fluvoxamine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Fluvoxamine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluvoxamine.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Fluvoxamine.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Fluvoxamine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fluvoxamine.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Fluvoxamine.
GenisteinThe metabolism of Genistein can be decreased when combined with Fluvoxamine.
GliclazideFluvoxamine may increase the hypoglycemic activities of Gliclazide.
GlimepirideFluvoxamine may increase the hypoglycemic activities of Glimepiride.
GlipizideFluvoxamine may increase the hypoglycemic activities of Glipizide.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Fluvoxamine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluvoxamine.
GlyburideFluvoxamine may increase the hypoglycemic activities of Glyburide.
GranisetronThe metabolism of Granisetron can be decreased when combined with Fluvoxamine.
GranisetronGranisetron may increase the serotonergic activities of Fluvoxamine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fluvoxamine.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Fluvoxamine.
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Fluvoxamine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluvoxamine.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Fluvoxamine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluvoxamine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Fluvoxamine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluvoxamine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluvoxamine.
HalothaneThe metabolism of Halothane can be decreased when combined with Fluvoxamine.
HeroinHeroin may increase the serotonergic activities of Fluvoxamine.
HeroinThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Heroin.
HesperetinThe metabolism of Hesperetin can be decreased when combined with Fluvoxamine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluvoxamine.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Fluvoxamine.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Fluvoxamine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Fluvoxamine.
HydrochlorothiazideFluvoxamine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Fluvoxamine.
HydrocodoneHydrocodone may increase the serotonergic activities of Fluvoxamine.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Fluvoxamine.
HydroflumethiazideFluvoxamine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Fluvoxamine.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Fluvoxamine.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Fluvoxamine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
HydroxyzineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Fluvoxamine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fluvoxamine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Fluvoxamine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Fluvoxamine.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Fluvoxamine resulting in a loss in efficacy.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fluvoxamine.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Fluvoxamine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluvoxamine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Fluvoxamine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Fluvoxamine.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Fluvoxamine.
IndalpineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Indalpine.
IndalpineIndalpine may increase the serotonergic activities of Fluvoxamine.
IndapamideFluvoxamine may increase the hyponatremic activities of Indapamide.
IndinavirThe metabolism of Indinavir can be decreased when combined with Fluvoxamine.
indisulamThe metabolism of indisulam can be decreased when combined with Fluvoxamine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fluvoxamine.
Insulin AspartFluvoxamine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirFluvoxamine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineFluvoxamine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineFluvoxamine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanFluvoxamine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproFluvoxamine may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Fluvoxamine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Fluvoxamine.
IproclozideIproclozide may increase the serotonergic activities of Fluvoxamine.
IproniazidIproniazid may increase the serotonergic activities of Fluvoxamine.
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Fluvoxamine.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Fluvoxamine.
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Fluvoxamine.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Fluvoxamine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluvoxamine.
IsoniazidThe metabolism of Fluvoxamine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Fluvoxamine.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fluvoxamine.
IsradipineThe metabolism of Isradipine can be decreased when combined with Fluvoxamine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Fluvoxamine.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Fluvoxamine.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Fluvoxamine.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Fluvoxamine.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Fluvoxamine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Fluvoxamine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluvoxamine.
KetamineThe metabolism of Ketamine can be decreased when combined with Fluvoxamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluvoxamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Fluvoxamine.
KetobemidoneKetobemidone may increase the serotonergic activities of Fluvoxamine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Fluvoxamine.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Fluvoxamine.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Fluvoxamine.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluvoxamine.
LabetalolThe metabolism of Labetalol can be decreased when combined with Fluvoxamine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fluvoxamine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluvoxamine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fluvoxamine.
LanreotideFluvoxamine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Fluvoxamine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Fluvoxamine.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Fluvoxamine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluvoxamine.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Fluvoxamine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fluvoxamine.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Fluvoxamine.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Fluvoxamine.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Fluvoxamine.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Fluvoxamine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluvoxamine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fluvoxamine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluvoxamine.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Fluvoxamine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Fluvoxamine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluvoxamine.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Fluvoxamine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Fluvoxamine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Fluvoxamine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fluvoxamine.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Fluvoxamine.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Fluvoxamine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Fluvoxamine.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Fluvoxamine.
LevorphanolLevorphanol may increase the serotonergic activities of Fluvoxamine.
LevorphanolThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Levorphanol.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluvoxamine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Fluvoxamine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluvoxamine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluvoxamine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fluvoxamine.
LinezolidLinezolid may increase the serotonergic activities of Fluvoxamine.
LinezolidThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluvoxamine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Fluvoxamine.
LiraglutideFluvoxamine may increase the hypoglycemic activities of Liraglutide.
LisurideThe metabolism of Lisuride can be decreased when combined with Fluvoxamine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fluvoxamine.
LofentanilLofentanil may increase the serotonergic activities of Fluvoxamine.
LofentanilThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lofentanil.
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Fluvoxamine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Fluvoxamine.
LomustineThe metabolism of Lomustine can be decreased when combined with Fluvoxamine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Fluvoxamine.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Fluvoxamine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluvoxamine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Fluvoxamine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluvoxamine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Fluvoxamine.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Fluvoxamine.
LosartanThe metabolism of Losartan can be decreased when combined with Fluvoxamine.
LovastatinThe metabolism of Lovastatin can be decreased when combined with Fluvoxamine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluvoxamine.
Lu AA21004The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lu AA21004.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Fluvoxamine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Fluvoxamine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluvoxamine.
MacitentanThe metabolism of Macitentan can be decreased when combined with Fluvoxamine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Magnesium Sulfate.
MalathionThe metabolism of Malathion can be decreased when combined with Fluvoxamine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Fluvoxamine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluvoxamine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Fluvoxamine.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Fluvoxamine.
MebanazineMebanazine may increase the serotonergic activities of Fluvoxamine.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Fluvoxamine.
MecaserminFluvoxamine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fluvoxamine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fluvoxamine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluvoxamine.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Fluvoxamine.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Fluvoxamine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluvoxamine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Fluvoxamine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fluvoxamine.
MenadioneThe metabolism of Menadione can be decreased when combined with Fluvoxamine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Fluvoxamine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluvoxamine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluvoxamine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Fluvoxamine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluvoxamine.
MestranolThe metabolism of Mestranol can be decreased when combined with Fluvoxamine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluvoxamine.
MetforminFluvoxamine may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the serotonergic activities of Fluvoxamine.
MethadoneThe metabolism of Methadone can be decreased when combined with Fluvoxamine.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Fluvoxamine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methadyl Acetate.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Fluvoxamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluvoxamine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluvoxamine.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Fluvoxamine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluvoxamine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluvoxamine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fluvoxamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluvoxamine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Fluvoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluvoxamine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Fluvoxamine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluvoxamine.
MethyclothiazideFluvoxamine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueFluvoxamine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Fluvoxamine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluvoxamine.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Fluvoxamine.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Fluvoxamine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Fluvoxamine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluvoxamine.
MetolazoneFluvoxamine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluvoxamine.
MetoprololThe metabolism of Fluvoxamine can be decreased when combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Fluvoxamine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluvoxamine.
MetyrosineFluvoxamine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluvoxamine.
MianserinThe metabolism of Mianserin can be decreased when combined with Fluvoxamine.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Fluvoxamine.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Fluvoxamine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluvoxamine.
MidazolamThe metabolism of Midazolam can be decreased when combined with Fluvoxamine.
MifepristoneFluvoxamine may increase the hypoglycemic activities of Mifepristone.
MiglitolFluvoxamine may increase the hypoglycemic activities of Miglitol.
MilnacipranThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Milnacipran.
MilnacipranMilnacipran may increase the serotonergic activities of Fluvoxamine.
MinaprineMinaprine may increase the serotonergic activities of Fluvoxamine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Fluvoxamine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Fluvoxamine.
MirtazapineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluvoxamine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fluvoxamine.
MoclobemideMoclobemide may increase the serotonergic activities of Fluvoxamine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Fluvoxamine.
ModafinilThe metabolism of Modafinil can be decreased when combined with Fluvoxamine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluvoxamine.
MontelukastThe metabolism of Montelukast can be decreased when combined with Fluvoxamine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Fluvoxamine.
MorphineMorphine may increase the serotonergic activities of Fluvoxamine.
MorphineThe metabolism of Morphine can be decreased when combined with Fluvoxamine.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Fluvoxamine.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluvoxamine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.
NabiloneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nabilone.
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Fluvoxamine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Fluvoxamine.
NalbuphineNalbuphine may increase the serotonergic activities of Fluvoxamine.
NalbuphineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluvoxamine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Fluvoxamine.
NaproxenThe metabolism of Naproxen can be decreased when combined with Fluvoxamine.
NaratriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Naratriptan.
NateglinideFluvoxamine may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Fluvoxamine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Fluvoxamine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluvoxamine.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Fluvoxamine.
NetupitantThe metabolism of Netupitant can be decreased when combined with Fluvoxamine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Fluvoxamine.
NialamideNialamide may increase the serotonergic activities of Fluvoxamine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Fluvoxamine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Fluvoxamine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Fluvoxamine.
NicotineThe metabolism of Nicotine can be decreased when combined with Fluvoxamine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Fluvoxamine.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Fluvoxamine.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Fluvoxamine.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Fluvoxamine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluvoxamine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluvoxamine.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Fluvoxamine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluvoxamine.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Fluvoxamine.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Fluvoxamine.
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Fluvoxamine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Fluvoxamine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluvoxamine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fluvoxamine.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Fluvoxamine.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Fluvoxamine.
NormethadoneNormethadone may increase the serotonergic activities of Fluvoxamine.
NormethadoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluvoxamine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Fluvoxamine.
OctamoxinOctamoxin may increase the serotonergic activities of Fluvoxamine.
OctreotideFluvoxamine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Fluvoxamine.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Fluvoxamine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluvoxamine.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Fluvoxamine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fluvoxamine.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Fluvoxamine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluvoxamine.
OpiumOpium may increase the serotonergic activities of Fluvoxamine.
OpiumThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Opium.
OrphenadrineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluvoxamine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluvoxamine.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Fluvoxamine.
OsimertinibThe serum concentration of Fluvoxamine can be decreased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Fluvoxamine.
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Fluvoxamine.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Fluvoxamine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluvoxamine.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Fluvoxamine.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Fluvoxamine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluvoxamine.
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Fluvoxamine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluvoxamine.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Fluvoxamine.
OxycodoneOxycodone may increase the serotonergic activities of Fluvoxamine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Fluvoxamine.
OxymorphoneOxymorphone may increase the serotonergic activities of Fluvoxamine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Fluvoxamine.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Fluvoxamine.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Fluvoxamine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluvoxamine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Fluvoxamine.
PalonosetronPalonosetron may increase the serotonergic activities of Fluvoxamine.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Fluvoxamine.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Fluvoxamine.
ParaldehydeFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fluvoxamine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Fluvoxamine.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Fluvoxamine.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Fluvoxamine.
PargylinePargyline may increase the serotonergic activities of Fluvoxamine.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Fluvoxamine.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Fluvoxamine.
ParoxetineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Paroxetine.
ParoxetineParoxetine may increase the serotonergic activities of Fluvoxamine.
PasireotideFluvoxamine may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluvoxamine.
Peginterferon alfa-2bThe serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineFluvoxamine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Fluvoxamine.
PentazocineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluvoxamine.
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Fluvoxamine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Fluvoxamine.
PerampanelThe metabolism of Perampanel can be decreased when combined with Fluvoxamine.
PergolideThe metabolism of Pergolide can be decreased when combined with Fluvoxamine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Fluvoxamine.
PermethrinThe metabolism of Permethrin can be decreased when combined with Fluvoxamine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fluvoxamine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluvoxamine.
PethidinePethidine may increase the serotonergic activities of Fluvoxamine.
PethidineThe metabolism of Pethidine can be decreased when combined with Fluvoxamine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Fluvoxamine.
PhenelzinePhenelzine may increase the serotonergic activities of Fluvoxamine.
PhenelzineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Fluvoxamine.
PhenindioneFluvoxamine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Fluvoxamine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluvoxamine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Fluvoxamine.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Fluvoxamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fluvoxamine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Fluvoxamine.
PhenprocoumonFluvoxamine may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Fluvoxamine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluvoxamine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluvoxamine.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Fluvoxamine.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Fluvoxamine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Fluvoxamine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluvoxamine.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Fluvoxamine.
PindololThe metabolism of Pindolol can be decreased when combined with Fluvoxamine.
PioglitazoneFluvoxamine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluvoxamine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Fluvoxamine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluvoxamine.
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Fluvoxamine.
PirlindolePirlindole may increase the serotonergic activities of Fluvoxamine.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Fluvoxamine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluvoxamine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Fluvoxamine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fluvoxamine.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Fluvoxamine.
PolythiazideFluvoxamine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluvoxamine.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Fluvoxamine.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Fluvoxamine.
PramipexoleFluvoxamine may increase the sedative activities of Pramipexole.
PramlintideFluvoxamine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluvoxamine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Fluvoxamine.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Fluvoxamine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluvoxamine.
PrazepamThe metabolism of Prazepam can be decreased when combined with Fluvoxamine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Fluvoxamine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fluvoxamine.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Fluvoxamine.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Fluvoxamine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluvoxamine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluvoxamine.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Fluvoxamine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fluvoxamine.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Fluvoxamine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluvoxamine.
ProcarbazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluvoxamine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Fluvoxamine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluvoxamine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fluvoxamine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluvoxamine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Fluvoxamine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Fluvoxamine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluvoxamine.
PropericiazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fluvoxamine.
PropofolThe metabolism of Propofol can be decreased when combined with Fluvoxamine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fluvoxamine.
PropranololThe metabolism of Propranolol can be decreased when combined with Fluvoxamine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluvoxamine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Fluvoxamine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluvoxamine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fluvoxamine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Fluvoxamine.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Fluvoxamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluvoxamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Fluvoxamine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluvoxamine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Fluvoxamine.
QuinethazoneFluvoxamine may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Fluvoxamine.
QuinidineThe metabolism of Fluvoxamine can be decreased when combined with Quinidine.
QuinineFluvoxamine may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Fluvoxamine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Fluvoxamine.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Fluvoxamine.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fluvoxamine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fluvoxamine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluvoxamine.
RanolazineThe metabolism of Fluvoxamine can be decreased when combined with Ranolazine.
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine.
RasagilineRasagiline may increase the serotonergic activities of Fluvoxamine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Fluvoxamine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Fluvoxamine.
RemifentanilRemifentanil may increase the serotonergic activities of Fluvoxamine.
RemifentanilThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluvoxamine.
RepaglinideFluvoxamine may increase the hypoglycemic activities of Repaglinide.
repinotanThe metabolism of repinotan can be decreased when combined with Fluvoxamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluvoxamine.
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Fluvoxamine.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Fluvoxamine.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Fluvoxamine.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Fluvoxamine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluvoxamine.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Fluvoxamine.
RiluzoleThe metabolism of Riluzole can be decreased when combined with Fluvoxamine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Fluvoxamine.
RiociguatThe metabolism of Riociguat can be decreased when combined with Fluvoxamine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Fluvoxamine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluvoxamine.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Fluvoxamine.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Fluvoxamine.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Fluvoxamine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluvoxamine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Fluvoxamine.
RoflumilastThe serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with Fluvoxamine.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Fluvoxamine.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Fluvoxamine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fluvoxamine.
RopiniroleFluvoxamine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Fluvoxamine can be decreased when combined with Ropinirole.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Fluvoxamine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluvoxamine.
RosiglitazoneFluvoxamine may increase the hypoglycemic activities of Rosiglitazone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluvoxamine.
RotigotineFluvoxamine may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Fluvoxamine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluvoxamine.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluvoxamine.
SafrazineSafrazine may increase the serotonergic activities of Fluvoxamine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fluvoxamine.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Fluvoxamine.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Fluvoxamine.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Fluvoxamine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluvoxamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluvoxamine.
SelegilineSelegiline may increase the serotonergic activities of Fluvoxamine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Fluvoxamine.
SelexipagThe metabolism of Selexipag can be decreased when combined with Fluvoxamine.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Fluvoxamine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fluvoxamine.
SertralineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sertraline.
SertralineThe metabolism of Fluvoxamine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluvoxamine.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Fluvoxamine.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Fluvoxamine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Fluvoxamine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluvoxamine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Fluvoxamine.
SimeprevirThe metabolism of Fluvoxamine can be decreased when combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Fluvoxamine.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Fluvoxamine.
SitagliptinFluvoxamine may increase the hypoglycemic activities of Sitagliptin.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Fluvoxamine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Fluvoxamine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fluvoxamine.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Fluvoxamine.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Fluvoxamine.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Fluvoxamine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fluvoxamine.
SparteineThe metabolism of Sparteine can be decreased when combined with Fluvoxamine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fluvoxamine.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Fluvoxamine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Fluvoxamine.
SufentanilSufentanil may increase the serotonergic activities of Fluvoxamine.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Fluvoxamine.
SulfadiazineFluvoxamine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleFluvoxamine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Fluvoxamine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Fluvoxamine.
SulfisoxazoleFluvoxamine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluvoxamine.
SumatriptanThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sumatriptan.
SunitinibFluvoxamine may increase the hypoglycemic activities of Sunitinib.
SuprofenThe metabolism of Suprofen can be decreased when combined with Fluvoxamine.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Fluvoxamine.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Fluvoxamine.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Fluvoxamine.
TacrineThe metabolism of Tacrine can be decreased when combined with Fluvoxamine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fluvoxamine.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Fluvoxamine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Fluvoxamine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Fluvoxamine.
TapentadolTapentadol may increase the serotonergic activities of Fluvoxamine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Fluvoxamine.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Fluvoxamine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fluvoxamine.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Fluvoxamine.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Fluvoxamine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluvoxamine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fluvoxamine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fluvoxamine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Fluvoxamine.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Fluvoxamine.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Fluvoxamine.
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Fluvoxamine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluvoxamine.
TemazepamThe metabolism of Temazepam can be decreased when combined with Fluvoxamine.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Fluvoxamine.
TeniposideThe metabolism of Teniposide can be decreased when combined with Fluvoxamine.
TenofovirThe metabolism of Fluvoxamine can be decreased when combined with Tenofovir.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Fluvoxamine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Fluvoxamine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Fluvoxamine.
TeriflunomideThe serum concentration of Fluvoxamine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Fluvoxamine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Fluvoxamine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluvoxamine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Fluvoxamine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluvoxamine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Fluvoxamine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluvoxamine.
ThalidomideFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fluvoxamine.
TheobromineThe metabolism of Theobromine can be decreased when combined with Fluvoxamine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fluvoxamine.
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Fluvoxamine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluvoxamine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluvoxamine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluvoxamine.
ThioproperazineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluvoxamine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluvoxamine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Fluvoxamine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluvoxamine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluvoxamine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluvoxamine.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Fluvoxamine.
TianeptineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tianeptine.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Fluvoxamine.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Fluvoxamine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fluvoxamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Fluvoxamine.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Fluvoxamine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Fluvoxamine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Fluvoxamine.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluvoxamine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fluvoxamine.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Fluvoxamine.
TolazamideFluvoxamine may increase the hypoglycemic activities of Tolazamide.
TolbutamideFluvoxamine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluvoxamine.
ToloxatoneToloxatone may increase the serotonergic activities of Fluvoxamine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Fluvoxamine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluvoxamine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluvoxamine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluvoxamine.
TorasemideThe metabolism of Torasemide can be decreased when combined with Fluvoxamine.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Fluvoxamine.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Fluvoxamine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Fluvoxamine.
TramadolTramadol may increase the serotonergic activities of Fluvoxamine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Fluvoxamine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Fluvoxamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tranylcypromine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Fluvoxamine.
TrazodoneThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trazodone.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Fluvoxamine.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Fluvoxamine.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Fluvoxamine.
TriamtereneThe metabolism of Triamterene can be decreased when combined with Fluvoxamine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluvoxamine.
TriazolamThe metabolism of Triazolam can be decreased when combined with Fluvoxamine.
TrichlormethiazideFluvoxamine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluvoxamine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluvoxamine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Fluvoxamine.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Fluvoxamine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluvoxamine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Fluvoxamine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluvoxamine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Fluvoxamine.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Fluvoxamine.
UdenafilThe metabolism of Udenafil can be decreased when combined with Fluvoxamine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fluvoxamine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fluvoxamine.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Fluvoxamine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluvoxamine.
ValsartanThe metabolism of Valsartan can be decreased when combined with Fluvoxamine.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Fluvoxamine.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Fluvoxamine.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Fluvoxamine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fluvoxamine.
VemurafenibThe serum concentration of Fluvoxamine can be increased when it is combined with Vemurafenib.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Fluvoxamine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Fluvoxamine.
VerapamilThe metabolism of Verapamil can be decreased when combined with Fluvoxamine.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Fluvoxamine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluvoxamine.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Fluvoxamine.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Fluvoxamine.
VilazodoneVilazodone may increase the serotonergic activities of Fluvoxamine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Fluvoxamine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fluvoxamine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Fluvoxamine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Fluvoxamine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Fluvoxamine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Fluvoxamine.
VortioxetineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Vortioxetine.
WarfarinFluvoxamine may increase the anticoagulant activities of Warfarin.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Fluvoxamine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fluvoxamine.
YohimbineThe therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Yohimbine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Fluvoxamine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Fluvoxamine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Fluvoxamine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluvoxamine.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Fluvoxamine.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Fluvoxamine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluvoxamine.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Fluvoxamine.
ZileutonThe metabolism of Zileuton can be decreased when combined with Fluvoxamine.
ZimelidineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Zimelidine.
ZimelidineZimelidine may increase the serotonergic activities of Fluvoxamine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluvoxamine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fluvoxamine.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Fluvoxamine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluvoxamine.
ZolpidemFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fluvoxamine.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Fluvoxamine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluvoxamine.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Fluvoxamine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluvoxamine.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Fluvoxamine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fluvoxamine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluvoxamine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluvoxamine.
Food Interactions
  • Avoid alcohol.
  • Avoid high doses of caffeine.
  • Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Kakiuchi T, Tsukada H, Fukumoto D, Nishiyama S: Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys. Synapse. 2001 Jun 1;40(3):170-9. [PubMed:11304754 ]
  2. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):383-6. [PubMed:11817517 ]
  3. Miolo G, Caffieri S, Levorato L, Imbesi M, Giusti P, Uz T, Manev R, Manev H: Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation. Eur J Pharmacol. 2002 Aug 30;450(3):223-9. [PubMed:12208313 ]
  4. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry. 2003 Apr;60(4):386-91. [PubMed:12695316 ]
  5. Inoue K: [Analysis and its application for prevention of side-effects of drugs and for evaluation of drug responsiveness]. Yakugaku Zasshi. 2004 Jun;124(6):293-9. [PubMed:15170064 ]
  6. McMahon LR, Cunningham KA: Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology. 2001 Mar;24(3):319-29. [PubMed:11166521 ]
  7. Millan MJ, Veiga S, Girardon S, Brocco M: Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Psychopharmacology (Berl). 2003 Aug;168(4):397-409. Epub 2003 Apr 30. [PubMed:12721776 ]
  8. Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. [PubMed:16316311 ]
  9. Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. [PubMed:18568110 ]
  10. Williams K, Wheeler DM, Silove N, Hazell P: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004677. doi: 10.1002/14651858.CD004677.pub2. [PubMed:20687077 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Rasmussen BB, Nielsen TL, Brosen K: Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol. 1998 Dec;83(6):240-5. [PubMed:9868741 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619 ]
  4. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  5. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  7. Yasui-Furukori N, Inoue Y, Kaneko S, Otani K: Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. J Pharm Biomed Anal. 2005 Feb 7;37(1):121-5. [PubMed:15664751 ]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 31, 2016 02:13